How Has Aquinox Performed Compared to Peers?

Gabriel Kane - Author

Nov. 20 2020, Updated 11:33 a.m. ET

Aquinox in comparison to industry ETF

The iShares Nasdaq Biotechnology ETF (IBB) has performed quite well with a PE (price-to-earnings) ratio of 85.21x and has given year-to-date net asset value of 22.46%, which is quite close to the NASDAQ Biotechnology Index of 22.73%.

In comparison with Aquinox, the iShares Nasdaq Biotechnology has outperformed the stock with an 8% rise in the price in 2Q15. Aquinox has fallen down by 16% in the same quarter. The company is still in the development stage, so it doesn’t yet have a PE ratio.

Article continues below advertisement

An analysis of Aquinox’s performance

Aquinox Pharmaceuticals’ (AQXP) competitors include Trillium Therapeutics (TRIL)(TRIL), Astellas Pharma (ALPMY), GlaxoSmithKline (GSK), Pfizer (PFE), Novartis (NVS), AstraZeneca (AZN), and Meda AB (MDABY).

We can compare Aquinox’s performance with Trillium (TRIL)(TRIL) and Astellas Pharma (ALPMY), as both these companies have negative EPS (earnings per share) and are in the growing stage. At the same time, Pfizer and GlaxoSmithKline have PEs of 24.1x and 7.16x, respectively. Both these companies are large-cap companies and have positive results due to a large number of products.

Future outlook

On the overall industry side, the company can increase their PE and EPS by achieving their break-even level, which also helps the company in expanding itself and increasing its profit. Aquinox has a positive future outlook and will likely continue to better its performance in the near future.


Latest Aquinox Pharmaceuticals Inc News and Updates

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.